Maxime Verhoeven

149 Cost-effectiveness of treat-to-target strategies over 5 years Supplementary Table 3 (continued) TCZ+MTX (n=106) TCZ (n=103) MTX (n=108) Total productivity loss costs $ - year 1 2,500 (2,100 to 3,000) 2,300 (1,800 to 2,800) 2,500 (2,100 to 3,000) - year 2 3,500 (2,800 to 4,300) 3,100 (2,400 to 3,800) 3,200 (2,500 to 3,900) - year 3 2,900 (2,400 to 3,500) 2,500 (2,000 to 3,100) 2,600 (2,100 to 3,200) - year 4 1,900 (1,500 to 2,300) 1,700 (1,300 to 2,100) 1,700 (1,300 to 2,000) - year 5 500 (200 to 900) 500 (100 to 1,100) 400 (200 to 600) - over 2 years 6,100 (5,000 to 7,200) 5,300 (4,300 to 6,500) 5,700 (4,600 to 6,800) - over 5 years 11,400 (9,300 to 13,700) 10,100 (8,000 to 12,400) 10,300 (8,300 to 12,500) Direct healthcare costs - year 1 6,100 (5,500 to 6,700) 7,200 (6,200 to 8,500) 7,000 (6,200 to 7,900) - year 2 18,000 (14,200 to 21,900) 6,700 (5,500 to 8,200) 8,400 (6,100 to 10,900) - year 3 15,200 (12,200 to 18,300) 6,400 (5,400 to 7,500) 7,600 (5,800 to 9,600) - year 4 10,600 (8,900 to 12,400) 6,000 (5,300 to 6,700) 6,500 (5,400 to 7,600) - year 5 4,500 (3,900 to 5,000) 5,400 (4,900 to 5,900) 5,000 (4,600 to 5,400) - over 2 years 24,100 (20,300 to 28,000) 14,000 (12,300 to 15,900) 15,400 (13,000 to 18,200) - over 5 years 54,400 (45,800 to 63,200) 31,800 (28,400 to 35,500) 34,500 (29,200 to 40,400) Indirect non-healthcare costs - year 1 1,100 (800 to 1,400) 1,600 (1,000 to 2,300) 1,500 (1,100 to 2,000) - year 2 300 (200 to 500) 600 (500 to 800) 500 (400 to 700) - year 3 700 (600 to 800) 900 (800 to 1,100) 1,200 (1,000 to 1,300) - year 4 1,400 (1,300 to 1,500) 1,600 (1,400 to 1,700) 2,500 (2,200 to 2,800) - year 5 2,400 (2,200 to 2,500) 2,400 (2,100 to 2,600) 4,300 (3,700 to 4,800) - over 2 years 1,400 (1,100 to 1,800) 2,200 (1,600 to 3,100) 2,100 (1,600 to 2,600) - over 5 years 5,900 (5,400 to 6,500) 7,100 (6,300 to 8,000) 10,000 (8,800 to 11,200) QALYs - year 1 0.69 (0.64 to 0.73) 0.70 (0.67 to 0.74) 0.64 (0.59 to 0.68) - year 2 0.82 (0.80 to 0.84) 0.78 (0.74 to 0.81) 0.82 (0.79 to 0.84) - year 3 0.74 (0.69 to 0.78) 0.75 (0.71 to 0.78) 0.72 (0.68 to 0.77) - year 4 0.72 (0.68 to 0.76) 0.70 (0.65 to 0.74) 0.74 (0.70 to 0.77) - year 5 0.70 (0.66 to 0.74) 0.66 (0.61 to 0.70) 0.70 (0.66 to 0.74) - over 2 years 1.51 (1.45 to 1.57) 1.48 (1.41 to 1.54) 1.45 (1.41 to 1.50) - over 5 years 3.67 (3.55 to 3.79) 3.58 (3.45 to 3.70) 3.61 (3.50 to 3.72) Outcomes based on single imputation nested in 10,000 bootstraps; costs expressed in euro’s. TCZ+MTX= initiation of tocilizumab + methotrexate strategy group; TCZ= initiation of tocilizumab + placebo- methotrexate strategy group; MTX= initiation of methotrexate + placebo-tocilizumab strategy group; total medication costs= all RA medication costs; other medication costs= all RA medication costs, without bDMARDs; productivity loss costs= costs related to work loss or being less productive; # = using human capital approach; $ = using friction cost approach, only counting costs for a period of absence up to 85 days; direct healthcare costs= all costs related to healthcare, also for other diseases (RA medication costs excluded); indirect non healthcare costs= costs related to patient and family (e.g., travel cost, buying stair lift, etc.); QALY= quality-adjusted life years [range 0-1, 1= full health]. 7